

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):  
**November 1, 2007**

**AVANT IMMUNOTHERAPEUTICS, INC.**

(Exact name of registrant as specified in charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-15006**  
(Commission file number)

**13-3191702**  
(IRS employer  
identification no.)

**119 Fourth Avenue**  
**Needham, Massachusetts 02494-2725**  
(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code:  
**(781) 433-0771**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On November 1, 2007, AVANT Immunotherapeutics, Inc. (the "Company") notified Select Vaccines Limited (ASX: SLT), an Australian biotechnology company ("SLT") that, effective December 31, 2007, the Company for strategic reasons is exercising its rights to terminate its Collaboration and License Agreement with SLT.

2

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**AVANT IMMUNOTHERAPEUTICS, INC.**

Dated: November 1, 2007

By: /s/ Avery W. Catlin  
Name: Avery W. Catlin  
Title: Senior Vice President and  
Chief Financial Officer

3